SRNE News and Press, Sorrento Therapeutics Inc. From 03/02/21

The FDA has cleared Sorrento Therapeutics (SRNE) to initiate clinical trail of internally developed anti-CD47 monoclonal antibody, STI-6643.The initial clinical trial will be a basket trial entitled “A Phase 1B, Open-Label, Dose-Escalation Study of the Safety and Efficacy of ...

Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial; No complicated titration or priming dose of the antibody is required to reduce toxicity; This study will be conducted at the Moffitt Cancer Center in Tampa, FL with Dr. David A. Sallman ...

Sorrento Therapeutics ([[SRNE]] +6.3%) and majority owned subsidiary Scilex Holdings company have entered into an exclusive licensing term sheet with Aardvark Therapeutics to acquire its proprietary formulation, ARD-301, for the treatment of chronic pain, fibromyalgia, and chronic post-C...

SAN DIEGO, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics (NASDAQ: SRNE, “Sorrento”) and Scilex Holdings Company (“Scilex”), a majority owned subsidiary of Sorrento, have entered into an exclusive licensing term sheet with Aardvark Therapeutics ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE). On May 15, 2020, news sources reporte...

Illumina and its short reading technology pushed the sequencing costs down during the last decade. Long reads and artificial intelligence are improving the sequencing and will likely keep driving the costs lower. Several companies are building business models around these technolo...

Beijing Yuanxin Technology raised $465 million in a Series E round to support its online/offline healthcare operations. Shanghai Microport Cardioflow Medtech, a spinout from China medical device maker Microport, completed a $324 million IPO in Hong Kong. Hangzhou Zhongmei Huadong ...

The company seemed to be a pump-and-dump case back in April 2020. However, a solid Covid-related pipeline seems to indicate that there is solid technology behind the company. The ability to grow the revenue around its Covid pipeline will serve as a proof-of-concept for this compan...

Sorrento Therapeutics ' (NASDAQ: SRNE) COVI-MSC seems likes promising therapy for COVID-19 after the first four patients treated with the stem cell therapy were released from the hospital. But in this video from Motley Fool Live , recorded on Feb. 1 , Fool.com contri...

Short sellers have their eyes peeled on Vir Biotechnology (NASDAQ: VIR) and Sorrento Therapeutics (NASDAQ: SRNE) . Short positions make up 22% and 26% of their float, respectively. Float refers to shares available for the general public to trade. The immediate risk lies ...